Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thrombocytopenia
Biotech
ASH: Novartis details ianalumab's phase 3 rare blood disease win
If the combo therapy's boosted platelet counts persist even longer, it could "change the treatment paradigm" for primary immune thrombocytopenia.
Darren Incorvaia
Dec 9, 2025 7:30am
Novartis scores 3rd phase 3 win for ianalumab this week
Aug 12, 2025 5:09am
Nuvectis axes ovarian cancer program after seeing phase 1b data
Jul 31, 2025 9:15am
Sanofi eyes broad portfolio for rilzabrutinib in immunology
Apr 23, 2021 10:00am
Sanofi snags speedy review for Principia BTK drug, Pompe program
Nov 18, 2020 10:34am
Argenx boosts pipeline with new version of lead drug
Jun 14, 2018 10:50am
